Demographics and clinical features of 55 aPL-positive patients with first observed pregnancies after the registry recruitment, by composite pregnancy morbidity (preterm live delivery at or before 37th week due to pre-eclampsia, small-for-gestational age, and/or placental insufficiency, or otherwise unexplained fetal death after the 10th week of gestation)
| N (%) | Composite pregnancy morbidity (N: 9) | No composite pregnancy morbidity (N: 46) |
| Demographics* | ||
| Race | ||
| White (n:33) | 4 (12%) | 29 (88%) |
| Latin American (n:9) | 0 | 9 (100%) |
| Asian (n:8) | 3 (38%) | 5 (63%) |
| Black (n:1) | 1 (100%) | 0 |
| Mean age at registry entry (years, mean±SD): 31.5±5.4 | 30±5.9 | 31.9±5.2 |
| Mean maternal age (years, mean±SD): 33.4±5.2 | 32.2±5.7 | 33.7±5.1 |
| Systemic autoimmune disease diagnosis | ||
| Primary APS† (n:31) | 5 (16%) | 26 (84%) |
| APS† with SLE (n:9) | 1 (11%) | 8 (89%) |
| Primary aPL-positivity (no APS) (n:10) | 1 (10%) | 9 (90%) |
| aPL-positivity (no APS) with SLE (n:5) | 2 (40%) | 3 (60%) |
| aPL/APS† Classification | ||
| Thrombotic and obstetrical APS† (n:14) | 1 (7%) | 13 (93%) |
| Thrombotic APS† (n:18) | 4 (22%) | 14 (78%) |
| Obstetrical APS† (n:8) | 1 (13%) | 7 (88%) |
| aPL without APS† (n:15) | 3 (20%) | 12 (80%) |
| Clinical characteristics | ||
| History of arterial thrombosis, venous thrombosis or microthrombosis (n:32) | 5 (16%) | 27 (84%) |
| 1 Event (n:18) | 2 (11%) | 16 (89%) |
| 2 Events (n:10) | 3 (30%) | 7 (70%) |
| 3 Events and more (n:4) | 0 | 4 (100%) |
| History of pregnancy (n:38) | 4 (11%) | 34 (89%) |
| Pregnancy morbidity (n:30) | 4 (13%) | 26 (87%) |
| No pregnancy morbidity (n:8) | 0 | 8 (100%) |
| Non-criteria manifestations | ||
| Thrombocytopenia (n:14) | 4 (29%) | 10 (71%) |
| Livedo reticularis (n:6) | 1 (17%) | 5 (83%) |
| White matter lesions (n:3) | 1 (33%) | 2 (67%) |
| Autoimmune haemolytic anaemia (n:2) | 1 (50%) | 1 (50%) |
| Cardiac valve disease (n:3) | 1 (33%) | 2 (67%) |
| aPL-nephropathy (n:1) | 1 (100%) | 0 |
| Laboratory characteristics | ||
| Triple aPL-positive (n:18) | 3 (17%) | 15 (83%) |
| LA-positive alone‡ (n:17): | 4 (24%) | 13 (76%) |
| Double aPL-positive (n:17) | 2 (12%) | 15 (88%) |
| LA+aCL (n:13) | 2 (15%) | 11 (85%) |
| aCL+aβ2GPI (n:2) | 0 | 2 (100%) |
| LA+aβ2GPI (n:2) | 0 | 2 (100%) |
*Eighteen of 55 were recruited from North America, 11 South America, 19 Europe and 7 Asia.
†APS based on the updated Sapporo classification criteria1
‡aCL and aβ2GPI not tested in two pregnancies; aβ2GPI not tested in three pregnancies.
aCL, anticardiolipin antibody; aPL, antiphospholipid antibodies; APS, antiphospholipid syndrome; aβ2GPI, anti-β2 glycoprotein-I antibody; LA, lupus anticoagulant.;